Envista Holdings Corporation
NVST
$24.03
-1.88%
Envista Holdings Corporation is a global dental products company that develops, manufactures, and markets consumables, equipment, and services to dental professionals across two reporting segments: Specialty Products & Technologies (dental implants, regenerative solutions, prosthetics, orthodontic brackets, aligners, and lab products) and Equipment & Consumables (imaging, treatment units, and infection prevention). Spun off from Danaher in 2019, Envista is a scaled but non-dominant player in a fragmented dental market, competing against larger diversified medtech names and specialized implant and aligner makers, with its identity anchored in a premium implant franchise (Nobel Biocare) layered atop a steadier, lower-margin equipment and consumables base. The current investor debate centers on whether the company's margin recovery and earnings inflection are durable or merely aided by one-off items, particularly after a Q3 2026 print that showed a dramatic jump in net income and EPS alongside only modest 3.2% revenue growth. Sentiment has been further shaped by soft dental demand commentary across the peer group, a mixed-to-cautiously-constructive sell-side stance, and a stock that has outperformed the market over the past year while lagging badly over the trailing three months.…
NVST
Envista Holdings Corporation
$24.03
Related headlines
Investment Opinion: Should I buy NVST Today?
Rating: Hold. The core thesis is that NVST is a genuinely de-rated asset — 1.34x PS, 1.17x book, 12.23x EV/EBITDA and roughly 12.4x the $1.97 consensus forward EPS — but the earnings inflection that would justify a re-rating is not yet proven, since Q3 2026's $3.16 EPS rests on a negative $81 million tax expense and $428.1 million of other expenses rather than operating leverage. With only 5 analysts covering and a consensus that is cautiously neutral (three constructive ratings, Baird's October 15 downgrade to Neutral, and post-earnings reiterations from UBS and Evercore on November 5 rather than upgrades), the evidence supports waiting for confirmation rather than pre-positioning. Specific price targets are not available in the provided data, so implied upside to a consensus target cannot be calculated; the $1.97 average EPS estimate and its unusually tight $1.954–$2.000 range are the best available anchor.
Supporting evidence for holding rather than selling is valuation and franchise quality: PS of 1.34x sits at the bottom of a multi-year range that ran from 10.66x in Q1 2023 to 5.09x in Q4 2024, and price-to-book of 1.17x is near book for a business with a 55.0% gross margin (57.93% in Q3 2026, within a 55.0%–57.9% band over four quarters). Revenue grew 3.22% year-over-year to $691.5 million, and the $3.159 billion consensus implies roughly 3% growth — steady but not accelerating. Balance sheet capacity is real (debt-to-equity 0.51, current ratio 2.38, $1.159 billion of cash), yet cash conversion is the weak link: TTM free cash flow of $226.2 million against a $3.65 billion market cap, quarterly FCF swinging from -$15.8 million in Q1 2026 to $88.5 million in Q2 and $61.8 million in Q3, ROE of just 1.51%, and $109 million of Q3 buybacks consuming the cash the business generates.
The biggest risks that would invalidate even this cautious stance are (1) the Q3 earnings beat being revealed as accounting noise, forcing consensus EPS toward the realistic 8.86%–10.99% operating margins seen in Q1–Q2 2026; (2) further softening in dental demand, which peer commentary already flags, hitting the $1.208 billion Specialty Products & Technologies segment that drives the higher-margin mix; and (3) the failed November 4 breakout to $27.19 fading back to $24.96, with the stock -12.75% over three months versus -2.83% for SPY. This Hold would upgrade to Buy if operating margins hold at or above roughly 11% for two consecutive quarters with positive free cash flow and revenue growth above 4%, or if the multiple compresses further toward 1.0x PS on stable estimates; it would downgrade to Sell if operating margin falls back below 8% or FCF turns negative again. Valuation verdict: the stock is cheap relative to its own history and roughly fair-to-cheap versus medtech peers on EV/EBITDA, but the discount reflects legitimate skepticism about earnings quality rather than an obvious mispricing.
Sign up to view all
NVST 12-Month Price Forecast
The forward view is balanced: the valuation is undemanding at 1.34x sales and roughly 12.4x the $1.97 consensus EPS, and the 55.0%–57.9% gross margin band plus a 0.51 debt-to-equity and 2.38 current ratio argue the franchise is intact. But the earnings inflection that would justify a re-rating is unproven, since Q3 2026's headline $3.16 EPS is inflated by a negative $81 million tax benefit and $428.1 million of other expenses while revenue grew just 3.22%. Sell-side sentiment is cautiously neutral with only 5 analysts, and the November 4 spike to $27.19 that faded to $24.96 shows the market is not yet willing to chase. I would upgrade to bullish if two consecutive quarters show operating margins at or above 11% with positive free cash flow and revenue growth above 4%; I would downgrade to bearish if operating margin falls below 8% or free cash flow turns negative again.
Wall Street consensus
Coverage is thin, with only 5 analysts contributing estimates, and the consensus is best characterized as cautiously neutral rather than bullish. The average forward EPS estimate is $1.97 (range $1.954–$2.000), and average estimated revenue is $3.159 billion (range $3.140 billion–$3.196 billion), implying roughly 3% growth — consistent with the recent trend but hardly a reacceleration story. Specific price targets are not available in the provided data, so implied upside to a consensus target cannot be calculated; based on the $1.97 EPS estimate and the stock's current 12.4x forward multiple, the market is not embedding aggressive multiple expansion. The institutional ratings skew mixed: of the ten most recent actions, roughly three are Outperform/Overweight (Evercore ISI, Leerink, JP Morgan), one is a downgrade to Neutral (Baird, from Outperform), and the remainder are Neutral/Market Perform/Hold (UBS, Piper Sandler, BMO, Needham).
The signal strength from the ratings flow is moderate and slightly deteriorating. JP Morgan's upgrade to Overweight from Neutral on September 3, 2026 is the most constructive recent datapoint, but it was offset by Baird's downgrade to Neutral from Outperform on October 15, and the November 5 post-earnings actions from UBS and Evercore were reiterations rather than changes — suggesting analysts are waiting for confirmation rather than adding conviction. With only 5 estimates, the EPS range is extremely tight ($1.954–$2.000, a spread of under 2.5%), which signals high conviction on near-term earnings but says little about the long-term trajectory. Limited coverage of this kind is typical of a mid-cap spin-off with a $3.65–$3.97 billion market cap; it implies less efficient price discovery and higher volatility around earnings, and investors should treat the neutral consensus as a signal that the market wants proof of durable margin recovery before re-rating the stock.
Bulls vs Bears: NVST Investment Factors
The bear case currently carries slightly stronger evidence because the dramatic Q3 2026 earnings jump is demonstrably distorted by a negative tax expense and $428.1 million of other expenses, while revenue growth of just 3.22% and erratic free cash flow (-$15.8 million in Q1, $61.8 million in Q3) offer no confirmation of durable improvement. The bull case rests on valuation: at 1.34x PS and 1.17x book, NVST sits at the bottom of its own multi-year range, and the tight $1.97 consensus EPS implies a 12.4x forward multiple that is undemanding if margins normalize. The single most important tension is whether the margin and earnings recovery is real and repeatable or merely one-off accounting noise — if management proves durable operating leverage on the next few prints, the de-rated multiple re-rates sharply; if not, the low valuation is a value trap. Sell-side sentiment (three constructive, one downgrade, several Neutral) and the failed November breakout reinforce that the market is waiting for confirmation rather than adding conviction.
Bullish
- Deep valuation de-rating to multi-year lows: NVST trades at just 1.34x price-to-sales and 1.17x price-to-book, versus PS ratios of 5.09x in Q4 2024 and 10.66x back in Q1 2023. For a business still generating a 55.0% gross margin, near-book valuation implies the market has already priced in substantial skepticism, leaving asymmetric upside if earnings normalize.
- Forward earnings imply sharp recovery: The five-analyst consensus EPS estimate of $1.97 against the $24.49 price implies roughly 12.4x forward earnings, a modest multiple for a healthcare supplies name. The EPS estimate range is extremely tight ($1.954–$2.000, under 2.5% spread), signaling high conviction that near-term earnings will recover materially from the distorted trailing $0.0129 EPS.
- Stable and premium gross margins: Gross margin has held in a tight 55.0%–57.9% band across the last four quarters, including 57.93% in Q3 2026 and 55.04% in Q4 2025. This consistency supports the premium implant franchise (Nobel Biocare) and suggests pricing power even amid soft dental demand.
- Solid balance sheet and liquidity: Debt-to-equity of 0.51 and a current ratio of 2.38, backed by $1.159 billion of cash at Q3 2026, give the company ample near-term flexibility. Management is also returning capital, repurchasing $109 million of stock in Q3 2026 and $103 million in Q2, which supports EPS.
Bearish
- Earnings quality is highly suspect: Q3 2026 net income of $508.3 million on $691.5 million of revenue implies a 73.5% net margin and $3.16 EPS, driven by a negative $81 million tax expense and $428.1 million of 'other expenses' flowing through the P&L. The realistic operating margins are far lower — 10.99% in Q2 2026 and 8.86% in Q1 — so the headline earnings jump is not representative of underlying operations.
- Anemic low-single-digit revenue growth: Q3 2026 revenue of $691.5 million grew only 3.22% year-over-year, and the consensus $3.159 billion revenue estimate implies roughly 3% growth. With the higher-margin Specialty Products & Technologies segment at $1.208 billion as the key swing factor, there is little cushion if dental demand softens further.
- Erratic and thin free cash flow: TTM free cash flow is $226.2 million, but quarterly FCF has swung from -$15.8 million in Q1 2026 to $88.5 million in Q2 and $61.8 million in Q3, with a $62.7 million working capital outflow dragging Q3 operating cash flow. ROE of just 1.51% and a PCF ratio of 13.23 confirm weak cash conversion relative to the equity base.
- Deteriorating sell-side conviction: Coverage is thin at only 5 analysts, and the ratings flow is mixed-to-deteriorating: Baird downgraded to Neutral from Outperform on October 15, 2026, offsetting JP Morgan's upgrade. Post-earnings actions from UBS and Evercore on November 5 were reiterations rather than upgrades, suggesting analysts want proof of durable margin recovery before re-rating.
NVST Technical Analysis
NVST is in a choppy, range-bound recovery rather than a clean uptrend. The stock is up 23.13% over the past year versus a 12.27% gain for SPY, a relative strength spread of roughly 10.86 points, yet it sits at $24.49, well below its 52-week high of $28.71 (set August 12, 2026) and comfortably above its 52-week low near $22.40 (June 3, 2026). That places the current price at approximately 33% of the 52-week range — closer to the lower quartile than the highs — which signals the year-long advance has stalled and the stock is consolidating rather than pressing to new highs. The maximum drawdown of -25.97% over the period underscores that this is a volatile, mean-reverting name rather than a steady compounder.
Short-term momentum has turned constructive even as the intermediate trend deteriorates, creating a notable divergence. The stock is up 7.32% over the past month against a -2.26% decline for SPY, a relative strength of +9.58 points, and is up 5.47% over six months (versus +2.13% for SPY). But the three-month change is -12.75% versus -2.83% for SPY, a -9.92 point relative drag, and YTD is +12.91% versus +10.62% for SPY. The pattern — strong 1-month bounce inside a weak 3-month slide — is characteristic of a mean-reversion rally off oversold conditions rather than a confirmed trend reversal; the November 4 spike to $27.19 (a single-session jump of roughly 9.8% from $24.77) that immediately faded back to $24.96 is a textbook failed breakout and argues for caution on chasing strength.
Key technical levels are well defined. Resistance sits at the $28.71 52-week high, with an intermediate ceiling near $28.37 (July 29) and the $27.19 November spike high; a decisive close above $28.71 would confirm a new leg higher and validate the year-long uptrend. Support rests at the $22.40 52-week low, with a nearer shelf around $22.61–$22.72 (mid-October) that has held on multiple tests. Beta is not available in the provided data, but the -25.97% max drawdown and the 9.8% single-day swing on November 4 imply materially above-market volatility, warranting smaller position sizing and wider stops than a typical large-cap medtech holding.
Beta
—
—
Max Drawdown
-26.0%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
+23.9%
Cumulative gain past year
| Period | NVST Return | S&P 500 |
|---|---|---|
| 1m | +4.9% | -3.0% |
| 3m | -13.6% | -3.6% |
| 6m | +1.1% | -0.2% |
| 1y | +23.9% | +10.1% |
| ytd | +10.8% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NVST Fundamental Analysis
Revenue is growing but only modestly, and the trajectory is uneven. Q3 2026 revenue of $691.5 million grew 3.22% year-over-year against $669.9 million in Q3 2025, and the sequential path has been lumpy: $705.5 million in Q1 2026, $730.5 million in Q2, then $691.5 million in Q3, with Q4 2025 at $750.6 million. Segment data shows Specialty Products & Technologies at $1.208 billion and Equipment & Consumables at $679.3 million, meaning the higher-margin implant and ortho franchise is the larger revenue driver and the key swing factor for growth. Low-single-digit top-line growth means the investment case rests on margin and earnings leverage rather than revenue acceleration, and the 3.2% pace leaves little cushion if dental demand softens further.
Profitability is the crux of the story, and the reported numbers are distorted by unusual items. Q3 2026 net income of $508.3 million on $691.5 million of revenue implies a 73.5% net margin and $3.16 EPS — figures that are clearly not representative of underlying operations, as evidenced by a negative $81 million tax expense and $428.1 million of "other expenses" flowing through the P&L. The cleaner read is the operating line: operating income of $515.2 million (74.5% operating margin) in Q3 is likewise inflated, while Q2 2026 operating income of $80.3 million (10.99% margin) and Q1 2026's $62.5 million (8.86% margin) are more realistic. Gross margin has been stable and healthy at 55.0%–57.9% across the last four quarters (57.93% in Q3 2026, 55.72% in Q2, 55.29% in Q1, 55.04% in Q4 2025), consistent with a premium dental franchise, but the gap between gross and operating margins reflects a heavy SG&A load ($284.2 million in Q3 alone).
Balance sheet and cash generation are adequate but not fortress-like. Debt-to-equity is 0.51, the current ratio is 2.38, and cash on hand was $1.159 billion at Q3 2026, giving solid near-term liquidity. Free cash flow is the weak spot: TTM FCF is $226.2 million, but quarterly FCF has been erratic — $61.8 million in Q3 2026, $88.5 million in Q2, and -$15.8 million in Q1 — and the Q3 operating cash flow of $77.9 million was dragged by a $62.7 million working capital outflow. ROE of just 1.51% and a PCF ratio of 13.23 confirm that cash conversion is thin relative to the equity base, and the company has been an active buyer of its own stock ($109 million repurchased in Q3 2026, $103 million in Q2), which supports EPS but consumes the very cash the business generates.
Quarterly Revenue
$691500000.0B
2026-10
Revenue YoY Growth
+3.2%
YoY Comparison
Gross Margin
57.9%
Latest Quarter
Free Cash Flow
$226200000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NVST Overvalued?
Because trailing net income is positive but anomalously small ($0.0129 EPS, 1.73% net margin), the trailing PE of 77.5x is essentially meaningless and I am leading with the price-to-sales ratio of 1.34x as the primary metric, cross-checked against EV/EBITDA of 12.23x. The forward PE of -0.74x is not usable as reported (it appears to reflect a negative or distorted forward earnings figure), and the PEG of -0.74 is likewise uninformative. The more telling signal is the analyst consensus EPS estimate of $1.97 for the forward period against a $24.49 price — implying roughly 12.4x forward earnings — which suggests the market is pricing in a sharp earnings recovery that the trailing numbers do not yet reflect.
On a peer basis, a 1.34x PS ratio and 12.23x EV/EBITDA are modest for a healthcare supplies company with a 55% gross margin. The PS multiple is well below the 4.7x–6.1x range the stock itself carried through 2025, and the EV/EBITDA of 12.2x is in line with or below where diversified dental and medtech peers typically trade. The 1.17x price-to-book is the standout — near book value for a business generating 55% gross margins is unusual and implies the market is discounting the durability of earnings. The premium/discount question is therefore less about paying up and more about whether the market is correctly skeptical of the earnings quality behind the recent headline numbers.
Historical context is the most important valuation lens here. NVST's PS ratio has compressed from 10.66x in Q1 2023 to 8.32x at year-end 2022, 5.09x at Q4 2024, and now 1.34x — a multi-year de-rating to the bottom of its own historical band. Similarly, price-to-book has fallen from 2.15x in Q1 2022 to 1.17x today, and the stock's historical PE has swung wildly (from 698.9x in Q4 2024 to 1.86x in Q3 2026) as earnings have been distorted by charges. Trading at the low end of its own valuation range can mean either a genuine value opportunity or that the market has permanently reset expectations for growth and margins; given only 3.2% revenue growth and erratic free cash flow, the burden of proof sits with management to demonstrate that the earnings recovery is real and repeatable.
PE
77.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 19x~54x
vs. Industry Avg
40.3x
Industry PE ~40.3x*
EV/EBITDA
12.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings quality and cash conversion. The Q3 2026 headline of $508.3 million net income and $3.16 EPS is inflated by a negative $81 million tax benefit and $428.1 million of other expenses, while realistic operating margins are only 8.86%–10.99% (Q1–Q2 2026); if investors mistake one-off items for recurring profitability, expectations could reset sharply lower. Free cash flow is erratic — -$15.8 million in Q1 2026 versus $88.5 million in Q2 and $61.8 million in Q3 — and TTM FCF of $226.2 million against a $3.65 billion market cap leaves thin cushion, especially as $109 million of Q3 buybacks consume the very cash the business generates. ROE of just 1.51% and a heavy SG&A load ($284.2 million in Q3 alone) mean the company depends on continued margin recovery to justify its valuation. Market and competitive risks stem from a premium valuation reset and soft end-market demand. Although the 1.34x PS and 12.23x EV/EBITDA are modest versus the stock's own 4.7x–6.1x historical PS range, that compression reflects a permanent reset of growth expectations rather than a temporary discount, and any re-rating requires proof of durable margins. Peer commentary is cautious — Zacks flagged XRAY's margin compression and soft dental demand while noting NVST's stronger momentum — and NVST competes against larger diversified medtech names and specialized implant and aligner makers in a fragmented market. Beta is not provided, but the -25.97% max drawdown and a 9.8% single-day swing on November 4 imply materially above-market volatility and sector-rotation sensitivity. The worst-case scenario is a chain in which the Q3 earnings beat is revealed as accounting noise, dental demand softens further, and analysts downgrade, compressing the multiple toward the low end. In that case the stock could retest its 52-week low of $22.40 (June 3, 2026), roughly -8.5% from the current $24.49, and a deeper demand shock could push toward the mid-teens, implying a -30% to -35% drawdown from current levels. The -25.97% historical max drawdown provides a realistic anchor for how far this name can fall in an adverse cycle.
FAQ
The most severe risk is earnings quality: Q3 2026 net income of $508.3 million on $691.5 million of revenue implies a 73.5% net margin, propped up by a negative $81 million tax expense and $428.1 million of other expenses, while realistic operating margins were 8.86% in Q1 and 10.99% in Q2 2026 — if the market re-bases expectations, the stock de-rates. Second is cash conversion and capital allocation: TTM free cash flow of $226.2 million against a roughly $3.65 billion market cap, quarterly FCF swinging from -$15.8 million to $88.5 million to $61.8 million, ROE of just 1.51%, and $109 million of Q3 buybacks consuming the cash the business generates. Third is demand and competitive risk in a fragmented dental market, where peer commentary (Zacks noted XRAY's margin compression and soft dental demand) flags a cautious end-market and the $1.208 billion Specialty Products & Technologies segment is the key swing factor. Fourth is sentiment and volatility risk: only 5 analysts cover the name, Baird downgraded to Neutral on October 15, 2026, the November 4 spike to $27.19 faded to $24.96, the stock is -12.75% over three months versus -2.83% for SPY, and the -25.97% max drawdown shows how far it can fall in an adverse cycle.
The 12-month forecast splits into three scenarios. The base case carries 55% probability with a $24.00–$28.00 range: revenue tracks the $3.159 billion consensus (about 3% growth), EPS lands near $1.97, operating margins normalize in the 9%–11% band, and the stock oscillates between the $22.40–$22.72 support shelf and the $28.37–$28.71 resistance band at roughly 12.4x forward earnings. The bull case has 25% probability and a $28.71–$32.00 range, requiring clean operating margins sustainably above 11%, revenue growth of 4%–5% on implant and orthodontic recovery, and a multiple re-rating from 1.34x PS toward 2.0x–2.5x. The bear case has 20% probability and a $17.00–$22.40 range, in which the Q3 beat is exposed as one-off accounting noise, dental demand softens further, and the multiple compresses toward the 52-week low and below. The base case is most likely, and its key assumption is that margins normalize rather than collapse — the single variable that determines whether the low valuation is an opportunity or a trap.
On most measures NVST screens as undervalued relative to its own history, though the discount is partly deserved. Price-to-sales of 1.34x compares with 5.09x in Q4 2024 and 10.66x in Q1 2023, price-to-book of 1.17x is down from 2.15x in Q1 2022, and EV/EBITDA of 12.23x is modest for a healthcare supplies business with a 55.0% gross margin. The trailing PE of 77.5x looks alarming but is meaningless because trailing EPS is only $0.0129 after charges, and the reported forward PE of -0.74x and PEG of -0.74 are distorted and unusable. The cleanest anchor is the $1.97 average analyst EPS estimate against the $24.49 price, implying about 12.4x forward earnings with an unusually tight $1.954–$2.000 estimate range. What the market is implying is skepticism: near-book valuation for a 55%-gross-margin franchise suggests investors doubt the durability of the earnings recovery and the 3% growth trajectory. If margins prove repeatable the stock is cheap; if Q3 was accounting noise, the low multiple is a value trap rather than a bargain.
From a risk/reward standpoint NVST is a reasonable but unproven buy candidate rather than a clear one. The upside case rests on valuation: 1.34x sales, 1.17x book and 12.23x EV/EBITDA sit at the bottom of a multi-year range that once reached 10.66x PS in Q1 2023, and the tight $1.97 consensus EPS implies roughly 12.4x forward earnings — an undemanding multiple if margins normalize. The downside is that the Q3 2026 headline $3.16 EPS was driven by a negative $81 million tax benefit and $428.1 million of other expenses, while revenue grew only 3.22% and free cash flow has been erratic (-$15.8 million in Q1 2026 versus $61.8 million in Q3). The realistic bear path is a retest of the $22.40 52-week low, about -8.5% from $24.49, with a deeper demand shock implying -30% to -35%. With only 5 analysts and a mixed-to-neutral consensus (Baird downgraded to Neutral on October 15, 2026), it is a good buy primarily for patient value investors who can wait for two consecutive quarters of 11%+ operating margins with positive free cash flow; it is not a good buy for anyone needing near-term catalysts or low volatility.
NVST is better suited to a medium-to-long-term holding than to short-term trading, though it is not a classic buy-and-hold compounder. It pays no dividend (payout ratio 0) and has no yield support, so total return depends entirely on price appreciation, and earnings visibility is limited by one-off items that have swung reported EPS from -$0.18 in Q3 2025 to $3.16 in Q3 2026. Volatility is well above market: the -25.97% max drawdown and the roughly 9.8% single-session jump on November 4 argue for smaller position sizing and wider stops than a typical large-cap medtech name. On the other hand, the one-year return of 23.13% versus 12.27% for SPY and the 7.32% one-month rebound against a -2.26% SPY decline show the name can reward patience when sentiment turns. A concrete minimum holding period of 12–24 months makes sense, giving management at least two to four quarters to prove durable 11%+ operating margins and consistent positive free cash flow; short-term traders should treat the $22.40–$22.72 support and $28.37–$28.71 resistance as the trading range rather than expecting a trend breakout.

